Format

Send to

Choose Destination
See comment in PubMed Commons below
Neurology. 2013 Aug 20;81(8):710-3. doi: 10.1212/WNL.0b013e3182a1aac7. Epub 2013 Jul 24.

Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica.

Author information

1
Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, China.

Abstract

OBJECTIVE:

To determine the effect of a lower dose of rituximab in depleting B lymphocytes, maintaining low B-cell counts, and relapse in patients with neuromyelitis optica (NMO) and NMO spectrum disorders.

METHODS:

We treated 5 Chinese patients with deteriorating NMO and NMO spectrum disorders with a 100-mg IV infusion of rituximab once a week for 3 consecutive weeks, followed by additional infusion of the same dosage depending on circulating B-cell repopulation.

RESULTS:

This reduced dosage of rituximab was sufficient to deplete B cells and maintain low B-cell counts. None of the treated patients experienced relapse, and all patients exhibited stabilized or improved neurologic function during the 1-year follow-up period. MRI revealed the absence of new lesions, no enhancement in spinal cord and brain, a significant shrinkage of spinal cord segments, and a reduction/disappearance of previous brain lesions.

CONCLUSION:

A lower dosage of rituximab may be sufficient in depleting B cells, maintaining low B-cell counts, and preventing disease progression in Chinese patients with NMO.

PMID:
23884041
PMCID:
PMC3776460
DOI:
10.1212/WNL.0b013e3182a1aac7
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center